Redefining Expectations in Rare Disease
Amicus Therapeutics (amicusrx.com) earns a Brand Analyzer score of 84 out of 100, placing it in the Strong Brand tier among Healthcare brands. Among 4664 Healthcare brands analyzed, Amicus Therapeutics ranks in the 87th percentile (category average 74, leader 96). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 80/100, Digital Presence 100/100, Visual Identity 97/100, Messaging Clarity 95/100, Trust Foundation 93/100, AI Discoverability 76/100, Brand Authority 55/100.
Amicus Therapeutics is a biotechnology company headquartered in Cranbury, United States, founded in 2002. It is a wholly owned subsidiary of BioMarin Pharmaceutical Inc. and focuses on developing and delivering innovative, genetically targeted therapies for people living with rare, genetically defined diseases. The company positions itself as dedicated to redefining expectations in rare disease treatment, serving patients, families, caregivers, and healthcare providers involved in diagnosing and treating these conditions.
| Brand Name | Amicus Therapeutics |
|---|---|
| Domain | amicusrx.com |
| Industry | Healthcare |
| Founded | 2002 |
| Headquarters | Cranbury |
| Parent Company / Owner | BioMarin Pharmaceutical Inc. |
| Main Competitors | Sanofi (Genzyme) (82/100), Takeda Pharmaceutical (87/100), Ultragenyx Pharmaceutical (79/100), Sarepta Therapeutics (83/100), PTC Therapeutics (85/100), Alnylam Pharmaceuticals (87/100), Chiesi Global Rare Diseases (75/100) |
Moz Domain Authority 49/100 vs category average 38 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #1,285,588 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
Amicus Therapeutics has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "Redefining Expectations in Rare Disease About Amicus Amicus is a wholly owned subsidiary of BioMarin Pharmaceutical Inc., a leading, global rare disease biotechnology company focus…" (No meta description. OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Apache, WordPress, Ghost.
Social footprint: verified profiles on Facebook, Instagram, YouTube, LinkedIn, X (Twitter); no detected presence on GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Amicus Therapeutics scores 58/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Amicus Therapeutics has a limited AI-visibility profile at 58/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (65/100) and its weakest is trust (46/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a global traffic rank of #1,285,588 (Tranco). The main gaps holding it back: no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Amicus Therapeutics from memory (August 2026) - a sign these signals are paying off.
Live results from asking a general-purpose AI assistant about the brand, checked August 2026.
When asked "What is Amicus Therapeutics?", Claude could identify the brand as of August 2026. Amicus Therapeutics is a biopharmaceutical company focused on developing therapies for rare genetic diseases, particularly lysosomal storage disorders. Its flagship product, Galafold (migalastat), is an oral therapy for Fabry disease, and it also markets Pombiliti plus Opfolda fo Best known for Developing Galafold, an oral precision medicine treatment for Fabry disease.
When asked "Best brands similar to Amicus Therapeutics?", Claude would recommend Amicus Therapeutics as of August 2026. It's a well recognized name in rare disease and lysosomal storage disorder treatment, so it would come up naturally alongside companies like Sanofi Genzyme or BioMarin.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Amicus Therapeutics's main competitors include Sanofi (Genzyme) (82/100), Takeda Pharmaceutical (87/100), Ultragenyx Pharmaceutical (79/100), Sarepta Therapeutics (83/100), PTC Therapeutics (85/100). These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Brand Analyzer scan
Amicus Therapeutics and Takeda Pharmaceutical are competitors in Healthcare. Brand Analyzer scores Amicus Therapeutics at 84/100 and Takeda Pharmaceutical at 87/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Brand Analyzer scan
Popular alternatives to Amicus Therapeutics include Sanofi (Genzyme) (82/100), Takeda Pharmaceutical (87/100), Ultragenyx Pharmaceutical (79/100), Sarepta Therapeutics (83/100), PTC Therapeutics (85/100). Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Brand Analyzer scan
Amicus Therapeutics is a biotechnology company focused on rare, genetically defined diseases. It is a wholly owned subsidiary of BioMarin Pharmaceutical Inc., headquartered in Cranbury, United States, and was founded in 2002.
Sources: Amicus Therapeutics official site
Amicus Therapeutics has moderate AI-search visibility, scoring 58/100 on Brand Analyzer's AI visibility composite (visibility 63, trust 46, recommendation 65). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Amicus Therapeutics official site
Amicus Therapeutics was founded in 2002. Amicus Therapeutics operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Amicus Therapeutics is headquartered in Cranbury. Amicus Therapeutics operates in the Healthcare category.
Sources: Wikidata
Amicus Therapeutics develops and delivers innovative, genetically targeted therapies aimed at transforming the lives of people living with rare diseases. As part of BioMarin Pharmaceutical, it combines scientific expertise with a global focus on rare disease research to address underserved patient populations.
Sources: Amicus Therapeutics official site
Amicus Therapeutics scores 65/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: Amicus Therapeutics official site
Amicus Therapeutics can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Amicus Therapeutics official site
Amicus Therapeutics' work is directed at patients, families, and caregivers affected by rare genetic diseases, as well as healthcare providers involved in diagnosing and treating these conditions.
Sources: Amicus Therapeutics official site
Amicus Therapeutics is known for its dedicated focus on rare, genetically defined diseases and for being a subsidiary of BioMarin Pharmaceutical, a global leader in rare disease biotechnology. The company emphasizes redefining expectations for patients and families affected by such conditions.
Sources: Amicus Therapeutics official site
Ranked closest to Amicus Therapeutics: Allergan (now part of AbbVie) (84/100), Allegheny Health Network (AHN) (84/100), Amplifon (84/100), Anritsu (84/100).
A step up - brands to learn from: theSkimm (91/100), Replika (91/100).
Category leader: Elsevier (96/100).